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Abstract 
Observational epidemiological evidence supports a linear inverse and independent 
association between serum total bilirubin levels and coronary heart disease (CHD) risk, but 
whether this association is causal remains to be ascertained. A Mendelian randomization 
approach was employed to test whether serum total bilirubin is causally linked to CHD. The 
genetic variant rs6742078 - well known to specifically modify levels of serum total bilirubin 
and accounting for up to 20% of the variance in circulating serum total bilirubin levels - was 
used as an instrumental variable. In pooled analysis of estimates reported from published 
genome-wide association studies, every copy of the T allele of rs6742078 was associated 
with 0.42 standard deviation (SD) higher levels of serum total bilirubin (95% confidence 
interval, 0.40 to 0.43).  Based on combined data from the Coronary Artery Disease Genome 
wide Replication and Meta-analyses and the Coronary Artery Disease (C4D) Genetics 
Consortium involving a total of  36 763 CHD cases and 76 997 controls, the odds ratio for 
CHD per copy of the T allele was 1.01 (95% confidence interval, 0.99 to 1.04). The odds 
ratio of CHD for a 1 SD genetically elevated serum total bilirubin level was 1.03 (95% 
confidence interval, 0.98 to 1.09). The current findings casts doubt on a strong causal 
association of serum total bilirubin levels with CHD. The inverse associations demonstrated 
in observational studies may be driven by biases such as unmeasured confounding and/or 
reverse causation. However, further research in large-scale consortia is needed. 
 
Keywords: Bilirubin; coronary heart disease; Mendelian randomization 
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Abbreviations 
BMI body mass index 
CARDIoGRAM Coronary Artery Disease Genome wide Replication and Meta-analyses  
CHD coronary heart disease 
CI confidence interval 
CVD cardiovascular disease 
GIANT Genetic Investigation of ANthropometric Traits 
GLGC Global Lipids Genetics Consortium 
GWAS genome-wide association studies 
HDL high-density lipoprotein 
HOMA-B homeostatic model assessment of beta-cell function 
HOMA-IR homeostatic model assessment of insulin resistance 
ICBP International Consortium for Blood Pressure 
MAGIC Meta-Analyses of Glucose and Insulin-related traits Consortium 
MR Mendelian randomization 
OR odds ratio 
SNP single-nucleotide polymorphism 
SD standard deviation 
SBP systolic blood pressure 
TG triglycerides 
WHR waist-to-hip ratio 
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Introduction 
There is an ongoing debate on the potential value of serum total bilirubin levels in 
cardiovascular disease (CVD) risk prevention (i.e., either as a causal therapeutic target or as a 
marker of risk prediction (1)). Recently, in a comprehensive assessment of the association of 
baseline serum total bilirubin levels with risk of future first-ever CVD events in the general 
population using a large population-based cohort study, a linear inverse and independent 
association has been demonstrated.(2) In the same study, a multivariate adjusted relative risk 
[95% confidence interval (CI)] for CHD of 0.95 (0.92 to 0.99) per 1 standard deviation (SD) 
increase in total bilirubin levels in pooled analysis of 8 population-based prospective studies 
was reported. The evidence is suggestive of causality, but it is not possible to make causal 
inferences using observational epidemiological studies, as such data are beset by residual 
confounding and reverse causation.(3, 4) In the absence of randomized controlled trials that 
offer the highest clinical evidence for assessing causality, integrative studies of genetic 
variants [single-nucleotide polymorphisms (SNPs] specifically related to serum bilirubin 
levels may provide another route to help judge whether bilirubin could be directly causal in 
CHD (i.e., “Mendelian randomization [MR] analysis”(5)).   
 
Serum bilirubin is under strong genetic regulation and shows a substantial variation among 
individuals. There are indications that a single gene locus [the uridine diphosphate 
glucuronyltransferase 1A1 (UGT1A1) on chromosome 2] accounts for a substantial 
proportion of the variation in serum bilirubin levels and is its major determinant.(6) A 
functional TATA box thymine adenine (TA) repeat variant in the promoter region of the 
UGT1A1 gene - UGT1A1*28 TATA box polymorphism - is known to significantly reduce 
UGT1A1 production and activity and is associated with unconjugated hyperbilirubinemia.(7, 
8) There are suggestions that this TA repeat variant might be the key polymorphism within 
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the UGT1A1 gene controlling serum bilirubin levels.(9) It has been hypothesized that the 
UGT1A1*28 allele may be a protective factor against CHD, which may provide support for a 
causal relationship between bilirubin and CHD risk. However, association studies 
investigating the UGT1A1 locus have provided conflicting but mostly null evidence for a 
potential protective effect of the UGT1A1*28 allele on CHD.(7, 8) The rs6742078 variant in 
the UGT1A1 gene [which has been shown to be in strong linkage disequilibrium with the 
UGT1A1*28 allele(10)] is well known to robustly and specifically modify levels of 
circulating serum levels of total bilirubin  (explaining up to 20% of the variation in total 
bilirubin levels(11)) and has been used as an instrument for examining the causal relevance of 
serum total bilirubin to disease outcomes.(11, 12) Stender and colleagues(12) have recently 
employed a MR approach using this variant as an instrumental variable and suggested a non-
causal association between total bilirubin and CHD risk. The authors called for further work 
to extend these findings. Using large-scale genetic data with increased power, this study 
aimed to assess the association of the UGT1A1 variant rs6742078 with CHD risk by utilising 
a MR approach. 
 
Methods and materials 
The rs6742078 was a suitable instrumental variable for the present analyses, given its robust 
specificity for serum total bilirubin levels and its use in previous MR studies.(11, 12) 
Estimates of the association of the genetic variant rs6742078 with CHD were extracted from 
publicly available data from two genetic consortia, comprising the Coronary Artery Disease 
Genome wide Replication and Meta-analyses (CARDIoGRAM),(13) and the Coronary 
Artery Disease (C4D) Genetics consortium.(14) Estimates of power to detect associations 
with CHD employed Purcell’s online power calculation for genetic studies.(15) Available 
genome-wide association studies (GWASs) reporting on the associations of the rs6742078 
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variant (or proxies, r2 = 1.0 with the index SNP based on the CEU Hap Map population) with 
serum total bilirubin levels at genome-wide significant levels (P < 5x10-8) were included in 
the present analyses. Studies were identified by searching the original publications of 
GWASs for serum total bilirubin levels that have been indexed by the National Human 
Genome Research Institute(NHGRI) GWAS catalogue.(16)  
 
The rs6742078 variant has been robustly demonstrated not to be associated with several 
cardiovascular risk markers that might confound the relationship between serum total 
bilirubin and CHD risk.(17, 18)  To further assess the scope for pleiotropic effects, 
associations of the rs6742078 variant with several cardiometabolic traits were explored using 
data from published GWASs available from http://csg.sph.umich.edu/locuszoom/.(19) A MR 
approach was employed which was based on the use of summary estimates for both 
rs6742078-serum total bilirubin and rs6742078-CHD associations. The MR estimate was 
derived using the Wald-type estimator,(20) given as: 
log OR CHD/serum total bilirubin = log OR CHD/allele / beta serum total bilirubin/allele 
Where log OR CHD/serum total bilirubin is the (log) increase of CHD risk per standard deviation 
(SD) increase in serum total bilirubin (MR estimate), log OR CHD/allele is the (log) increase in 
CHD risk per allele (rs6742078-CHD association), and beta serum total bilirubin/allele is the number 
of SDs above the mean serum total bilirubin level per allele (rs6742078-serum total bilirubin 
association). The standard error of the MR estimate was estimated using the Delta 
method.(21, 22) 
 
Results 
As expected, there was no evidence of associations of the rs6742078 variant with any of the 
cardiovascular risk markers assessed (Figure 1). An estimate of the effect of the variant on 
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serum total bilirubin levels was based on pooled analysis of estimates reported from previous 
GWASs (Table 1). The pooled effect on serum total bilirubin levels, expressed as per SD 
higher change, was 0.42 (95% CI, 0.40-0.43) for each copy of the T allele, with estimates 
ranging from 0.29 to 0.57 SD across studies. The estimate of the effect on CHD risk was 
based on combined data from CARDIoGRAM and C4D consortia comprising of 36,763 
CHD cases and 76,997 controls. The pooled OR for CHD per copy of the T allele was 1.01 
(95% CI, 0.99-1.04).  The statistical power of the genotype-CHD association to reliably 
detect the anticipated OR per minor allele was 94% (minor allele frequency for rs6742078 
was 33%).  The causal OR for CHD was estimated as 1.03 (95% CI, 0.98-1.09) per 1 SD 
increase in serum total bilirubin level, which is in contrast to the pooled estimate of 0.95 
(95% CI, 0.92-0.99) from observational evidence (2) (Figure 2). 
 
Discussion 
Utilizing large-scale genetic data and a MR approach, the MR estimate showed no strong 
evidence of a causal effect of serum total bilirubin on risk of CHD, which is consistent with 
results of the recent MR study,(12) and in contrast to epidemiological evidence from 
observational studies.(2) The current findings are important and less prone to bias than results 
from traditional observational epidemiology, because causal investigations with the use of the 
UGT1A1 variant are likely to be free from confounding, not subject to reverse-causation, and 
genetically-elevated serum levels of total bilirubin are indicative of life-long levels.  
 
The analysis presented has strengths and limitations which merit consideration. The 
rs6742078 variant was found to be particularly informative because it is exclusively 
associated with substantial increases in total bilirubin. Additionally, a comprehensive 
assessment of the independence of this variant was conducted using published data from 
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several large-scale GWASs. Though this analysis was more adequately powered than the 
previous study, both analyses employed a single instrumental variable MR approach which 
may have limited the findings, given the lack of specificity often observed with single 
SNPs.(23) Mendelian randomisation analyses using multiple SNPs that are each inherited 
independently and affecting serum total bilirubin levels additively (allele scores) may be 
needed to rule out any causal relevance of serum total bilirubin levels to CHD risk. 
Furthermore, in the current analyses, a MR approach was employed using summarized 
published and publicly available data which precluded the ability to fully assess instrumental 
variable assumptions; adequately address population stratification; test for the attenuation of 
genetic associations with the outcome on adjustment for the exposure of interest; and assess 
parametric assumptions required by instrumental variable methods for effect estimation.(24) 
However, it has been reported that causal estimates from summarized data are almost as 
precise as those obtained from individual-level data.(24) The results should still be 
interpreted in context of these limitations. MR investigations using individual-level data may 
provide another efficient method to help establish or rule out causality.  
 
In conclusion, the current findings do not provide strong evidence for a causal association 
between serum total bilirubin levels and CHD. The inverse associations demonstrated in 
observational studies may be driven by biases such as unmeasured confounding and/or 
reverse causation. However, given the limitations of the present study and that serum total 
bilirubin remains a promising though unproven strategy in the prevention of CHD, further 
evaluation may be warranted. 
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Figure legends 
Figure 1. Regional association plots of rs6742078 with cardiometabolic traits 
Plots were created with LocusZoom available from http://csg.sph.umich.edu/locuszoom using published data 
from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC); Global Lipids Genetics 
Consortium (GLGC); Genetic Investigation of ANthropometric Traits (GIANT); and the International 
Consortium for Blood Pressure (ICBP). 
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin ; HDL, high-density lipoprotein; HOMA-
B, homeostatic model assessment of beta-cell function; HOMA-IR,  homeostatic model assessment of insulin 
resistance; SBP, systolic blood pressures; TG, triglycerides; WHR, waist-to-hip ratio 
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Figure 2. Comparison of the associations of circulating and genetically elevated serum total 
bilirubin levels with coronary heart disease 
Higher circulating serum total bilirubin
Genetically elevated serum total bilirubin
Exposure
4,994 / 72,781
36,763 / 76,997
CHD cases / controls
0.95 (0.91, 0.99)
1.03 (0.98, 1.09)
Odds Ratio (95% CI)
1.9 1.05 1.15
Odds Ratio (95% CI) per 1SD higher serum total bilirubin levels
 
CHD, coronary heart disease; CI, confidence interval; SD, standard deviation 
 
Table 1. Table of the rs6742078 variant or proxies confirmed to be associated with serum total bilirubin levels at genome-wide significance in 
published studies 
  
GWAS study (reference) Population Sample 
(N) 
Lead SNP Effect 
allele or 
minor 
allele 
Effect 
allele 
frequency  
Variance 
explained 
% 
beta (SE) or effect 
(95% CI) per copy 
effect allele [unless 
otherwise specified] 
P-value for 
association 
with total 
bilirubin 
         
Johnson et al., 2009 (1) Europeans 9,464 rs6742078 T 0.32 18.0 0.234 (0.005)† < 5.0E-324 
Sanna et al., 2009 (2) Sardinians 4,300 rs887829 T 0.30 14.3 0.57 (0.032)* 6.21E-62 
Chen et al., 2012 (3) African-Americans 619 rs887829 T 0.45 12.4 0.226 (0.183, 0.270) 1.97E-22 
Bielinski et al., 2011 (4) North-American 6,307 rs4148325 T 0.33 18 0.17 (0.0098)† 4.96E-62 
Dai et al., 2013 (5) Han-Chinese 10,282 rs6742078 A 0.12 4.7 0.153 (0.008)† 1.44E-89 
                           †, beta or effect size represents change in log transformed bilirubin per copy effect allele; *, change in standard deviation units 
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